|
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Textual) (USD $)
|
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Jun. 30, 2014
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
| GST tax receivable | $ 2,044us-gaap_ValueAddedTaxReceivable | $ 2,044us-gaap_ValueAddedTaxReceivable | $ 946us-gaap_ValueAddedTaxReceivable | |||
| Income Tax Expense (Benefit) | 82,440us-gaap_IncomeTaxExpenseBenefit | 48,451us-gaap_IncomeTaxExpenseBenefit | 82,440us-gaap_IncomeTaxExpenseBenefit | 48,451us-gaap_IncomeTaxExpenseBenefit | ||
| Research and development | 2,443us-gaap_ResearchAndDevelopmentExpense | 0us-gaap_ResearchAndDevelopmentExpense | 6,322us-gaap_ResearchAndDevelopmentExpense | 0us-gaap_ResearchAndDevelopmentExpense | ||
| Write Off of Capitalized Patent Costs | $ 27,000ppch_writeOffOfCapitalizedPatentCosts | |||||
| Common Stock [Member] | ||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount |
432,163,062us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember |
432,163,062us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_StatementEquityComponentsAxis = us-gaap_CommonStockMember |
||||
| Warrant [Member] | ||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount |
3,000,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_StatementEquityComponentsAxis = us-gaap_WarrantMember |
3,000,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_StatementEquityComponentsAxis = us-gaap_WarrantMember |
||||
| X | ||||||||||
|
- Definition
Write-off of amounts previously capitalized as patent costs related to various applications. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|